Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 5,050,505 shares of common stock of Agios Pharmaceuticals, Inc. for approximately $234.6 million. The common stock is listed on the NASDAQ Global Select Market under the symbol “AGIO.”

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associates Ferrell Maguire Keel and Jaryn S. Fields. The tax team included partner Michael Mollerus and associate Dao Fu. Associates Bonnie Chen and Paul S. Lee provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post